Institute Of Biomedical Research (MRES) Stock Price, News & Analysis
Company Description
Institute Of Biomedical Research (OTC Link: MRES) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $18.4M.
MRES has declined 89.2% over the past year. Shares last traded at $0.0012.
This page collects what Stock Titan holds for MRES, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Institute Of Biomedical Research (MRES) stock last closed at $0.0012. Over the past 12 months, the stock has lost 89.2%. At a market capitalization of $18.4M, MRES is classified as a micro-cap stock with approximately 2.9B shares outstanding.
Latest News
Institute Of Biomedical Research has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 6 with negative movement. Key topics include acquisition. View all MRES news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Short interest in Institute Of Biomedical Research (MRES) currently stands at 480.8 thousand shares, a new position with no short interest reported in the previous period, representing 0.0% of the float. Since July 2025, short interest has increased by 4833.5%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Institute Of Biomedical Research (MRES) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.
MRES Company Profile & Sector Positioning
Institute Of Biomedical Research (MRES) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing MRES often look at related companies in the same sector, including Rapid Dose Thera (RDTCF), Finch Therapeutics Group, Inc. (FNCH), Biomind Labs Inc (BMNDF), Pharmather Holdings Ltd (PHRRF), and Oncotelic Therapeutics Inc (OTLC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MRES's relative position within its industry.